About MEI Pharma (NASDAQ:MEIP)
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MEIP
- CUSIP: N/A
- Web: www.meipharma.com
- Market Cap: $99.03 million
- Outstanding Shares: 36,950,000
- 50 Day Moving Avg: $2.63
- 200 Day Moving Avg: $2.32
- 52 Week Range: $1.34 - $3.26
Sales & Book Value:
- Trailing P/E Ratio: 38.29
- Foreward P/E Ratio: -1.94
- P/E Growth: 22.80
- Annual Revenue: $23.25 million
- Price / Sales: 4.26
- Book Value: $1.38 per share
- Price / Book: 1.94
- EBITDA: $2.47 million
- Net Margins: 11.48%
- Return on Equity: 5.26%
- Return on Assets: 4.55%
- Current Ratio: 11.38%
- Quick Ratio: 11.38%
- Average Volume: 235,143 shs.
- Beta: 1.59
- Short Ratio: 0.64
Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma, Inc. (NASDAQ:MEIP) issued its earnings results on Tuesday, September, 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.60 million. MEI Pharma had a return on equity of 5.26% and a net margin of 11.48%. View MEI Pharma's Earnings History.
Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?
2 brokers have issued 1-year price objectives for MEI Pharma's shares. Their predictions range from $6.50 to $7.00. On average, they anticipate MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.
What are analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (9/9/2017)
- 2. Cann analysts commented, "MEI Pharma and partner Helsinn presented positive findings at the European Hematology Association (EHA) meeting in Madrid, Spain from a genetic mutation analysis of patients in a phase II clinical study of the investigational drug pracinostat and azacitidine in acute myeloid leukemia (AML). These data were previously presented at ASCO in early June 2017. These data support our outlook that Helsinn could launch Pracinostat for the treatment of AML and other potential indications in calendar Q1 2022. Potential sales will be recognized in the form of royalty income by MEI Pharma." (6/26/2017)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Tocagen (TOCA), Ovid Therapeutc (OVID), Fate Therapeutics (FATE), Recro Pharma (REPH), Agile Therapeutics (AGRX), Vascular Biogenics (VBLT), Summit Therapeutics PLC (SMMT), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), Conatus Pharmaceuticals (CNAT), Adverum Biotechnologies (ADVM), Dimension Therapeutics (DMTX), Cempra (CEMP), Verastem (VSTM), XBiotech (XBIT), Cellular Biomedicine Group (CBMG), Immune Design Corp. (IMDZ) and Verona Pharma Plc (VRP).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Christine Anna White M.D., Independent Chairman of the Board
- Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
- Brian G. Drazba, Chief Financial Officer, Secretary
- David M. Urso, Senior Vice President of Corporate Development, General Counsel
- Robert D. Mass M.D., Chief Medical Officer
- Charles V. Baltic III, Independent Director
- Kevan E. Clemens Ph.D., Independent Director
- Nicholas R. Glover Ph.D., Independent Director
- Thomas C. Reynolds M.D. Ph.D., Independent Director
- William Dodge Rueckert, Independent Director
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MEI Pharma stock can currently be purchased for approximately $2.68.
Consensus Ratings for MEI Pharma (NASDAQ:MEIP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$6.75 (151.87% upside)|Consensus Price Target History for MEI Pharma (NASDAQ:MEIP)
Analysts' Ratings History for MEI Pharma (NASDAQ:MEIP)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/14/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$7.00||Low|
Earnings History for MEI Pharma (NASDAQ:MEIP)Earnings History by Quarter for MEI Pharma (NASDAQ MEIP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/5/2017||Q4 2017||($0.15)||($0.12)||$0.60 million||$0.45 million||View||Listen|
|5/4/2017||Q3 2017||($0.03)||($0.02)||$5.00 million||$4.51 million||View||N/A|
|2/8/2017||Q217||($0.29)||$0.32||$1.25 million||$17.20 million||View||N/A|
|11/8/2016||Q1 2017||($0.14)||($0.12)||$0.63 million||$1.10 million||View||N/A|
Earnings Estimates for MEI Pharma (NASDAQ:MEIP)
2017 EPS Consensus Estimate: ($0.10)
2018 EPS Consensus Estimate: ($0.63)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)
Insider Ownership Percentage: 4.62%Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership Percentage: 17.93%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/9/2015||Vivo Ventures Vii, Llc||Major Shareholder||Sell||390,572||$1.84||$718,652.48|| |
|1/21/2015||Charles V Baltic III||Director||Buy||5,000||$3.81||$19,050.00|| |
|12/9/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||79,085||$6.01||$475,300.85|| |
|12/8/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||9,004||$6.05||$54,474.20|| |
|6/30/2014||Charles V Baltic III||Director||Buy||2,000||$6.56||$13,120.00|| |
|10/29/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||299,609||$8.21||$2,459,789.89|| |
|10/2/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||581,646||$10.16||$5,909,523.36|| |
|8/16/2013||Charles V Baltic III||Director||Buy||2,600||$6.82||$17,732.00|| |
|6/28/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||7,337||$7.58||$55,614.46|| |
|6/11/2013||Vivo Ventures V, Llc||Major Shareholder||Sell||13,727||$7.80||$107,070.60|| |
|5/16/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||17,428||$9.07||$158,071.96|| |
|5/8/2013||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||200,000||$8.58||$1,716,000.00|| |
|1/25/2013||Charles V Baltic III||Director||Buy||10,200||$6.04||$61,608.00|| |
|12/21/2012||Charles V Baltic III||Director||Buy||3,500||$7.18||$25,130.00|| |
Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
Loading headlines, please wait.
MEI Pharma (MEIP) Chart for Monday, October, 23, 2017